Phaseline

Targets › TACR1

TACR1 (Substance-P receptor): drug programs, companies and trials

8 programs from 8 companies in 12 trials: 6 Phase 2, 4 Phase 3, 1 Phase 1, 1 Phase 4; Other, Metabolic and endocrine, Genitourinary; next expected readout Dec 2026.

Receptor for the tachykinin substance P, also able to bind and respond to tachynins neurokinin A/substance K and neurokinin B/neuromedin-K. The rank order of affinity of this receptor to tachykinins is: substance P > neurokinin A/substance K > neurokinin B/neuromedin-K. Substance P binding to its receptor triggers G protein-coupled receptor signaling via activation of phosphatidylinositol hydrolysis by phospholipase…. (UniProt, P25103)

Open in Phaseline: the race on TACR1, likelihood bands and readouts

Programs

CompanyDrugTargetsHighest phaseConditionsNext expected readout
Shanghai 6th People's HospitalFosaprepitant
Neurokinin 1 receptor antagonist
TACR1Phase 4Chemotherapy-induced Nausea and VomitingDec 2026
Vanda PharmaceuticalsTradipitant
Neurokinin 1 receptor antagonist
TACR1Phase 3Idiopathic Gastroparesis; Nausea and Vomiting; Motion SicknessDec 2026
BayerElinzanetant (BAY3427080)
Neurokinin 1 receptor antagonist; Neurokinin 3 receptor antagonist
TACR1, TACR3Phase 3Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer; Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women; Menopause-related Hot FlashesFeb 2027
IWK Health CentreAprepitant
Neurokinin 1 receptor antagonist
TACR1Phase 2Spinal FusionMar 2027
Montefiore Medical CenterFosaprepitant
Neurokinin 1 receptor antagonist
TACR1Phase 2Nausea and VomitingMar 2027
University Hospital, RouenAprepitant
Neurokinin 1 receptor antagonist
TACR1Phase 2Apnea, ObstructiveJun 2027
Helsinn HealthcareFosnetupitant
Neurokinin 1 receptor antagonist
TACR1Phase 2Nausea and Vomiting Chemotherapy-InducedOct 2027
Tianjin Medical University Cancer Institute and HospitalFosrolapitant
NK1 receptor antagonist
TACR1Phase 2Chemotherapy-Induced Nausea and Vomiting (CINV)Jun 2028

Conditions

Nausea and Vomiting (2) Nausea and Vomiting Chemotherapy-Induced (1) Idiopathic Gastroparesis (1) Motion Sickness (1) Vasomotor Symptoms Caused by Adjuvant Endocrine Therapy in Women With, or at High Risk for Developing Hormone-receptor Positive Breast Cancer (1) Vasomotor Symptoms as a Sex Hormone-dependent Disorder in Women (1) Menopause-related Hot Flashes (1) Apnea, Obstructive (1) Chemotherapy-Induced Nausea and Vomiting (CINV) (1) Spinal Fusion (1) Chemotherapy-induced Nausea and Vomiting (1)

Modalities

small molecule (8)

Companies

Helsinn Healthcare (1) Vanda Pharmaceuticals (1) Bayer (1) University Hospital, Rouen (1) Tianjin Medical University Cancer Institute and Hospital (1) IWK Health Centre (1) Shanghai 6th People's Hospital (1) Montefiore Medical Center (1)

Related targets

TACR3 (1)

Programs group each company's trials by drug; targets and mechanisms come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood is in the app.